View in EDS HTML Full Text PDF Full Text

Donanemab in Alzheimer's disease: Promise, limitations, and implementation challenges in Australia.

Saved in:
Bibliographic Details
Title: Donanemab in Alzheimer's disease: Promise, limitations, and implementation challenges in Australia.
Authors: Dawood, Muhammad (AUTHOR), Saqib, Hasnain Wajeeh (AUTHOR)
Source: Australasian Psychiatry. Apr2026, Vol. 34 Issue 2, p199-199. 1p.
Subjects: Alzheimer's disease, Therapeutic use of monoclonal antibodies, Infusion therapy, Clinical trials, Biomarkers, Magnetic resonance imaging, Health equity, Amyloid plaque
Geographic Terms: Australia
Abstract: The article focuses on the recent approval of donanemab, a monoclonal antibody targeting insoluble amyloid-β plaques, for early Alzheimer's disease (AD) treatment in Australia. While the TRAILBLAZER-ALZ 2 trial demonstrated donanemab's ability to slow cognitive and functional decline, its use involves challenges such as amyloid-related imaging abnormalities requiring intensive MRI monitoring and limited applicability to diverse populations. Practical barriers include the need for specialized infusion facilities, biomarker testing, and high costs without subsidy, raising equity concerns, especially in rural areas. The article emphasizes that donanemab is not curative and highlights the importance of preventive care, symptomatic management, and culturally sensitive, coordinated strategies to ensure equitable access and effective dementia care. [Extracted from the article]
Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 192851254
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Donanemab in Alzheimer's disease: Promise, limitations, and implementation challenges in Australia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Dawood%2C+Muhammad%22">Dawood, Muhammad</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saqib%2C+Hasnain+Wajeeh%22">Saqib, Hasnain Wajeeh</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Australasian+Psychiatry%22">Australasian Psychiatry</searchLink>. Apr2026, Vol. 34 Issue 2, p199-199. 1p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Alzheimer's+disease%22">Alzheimer's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutic+use+of+monoclonal+antibodies%22">Therapeutic use of monoclonal antibodies</searchLink><br /><searchLink fieldCode="DE" term="%22Infusion+therapy%22">Infusion therapy</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink><br /><searchLink fieldCode="DE" term="%22Biomarkers%22">Biomarkers</searchLink><br /><searchLink fieldCode="DE" term="%22Magnetic+resonance+imaging%22">Magnetic resonance imaging</searchLink><br /><searchLink fieldCode="DE" term="%22Health+equity%22">Health equity</searchLink><br /><searchLink fieldCode="DE" term="%22Amyloid+plaque%22">Amyloid plaque</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Australia%22">Australia</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The article focuses on the recent approval of donanemab, a monoclonal antibody targeting insoluble amyloid-β plaques, for early Alzheimer's disease (AD) treatment in Australia. While the TRAILBLAZER-ALZ 2 trial demonstrated donanemab's ability to slow cognitive and functional decline, its use involves challenges such as amyloid-related imaging abnormalities requiring intensive MRI monitoring and limited applicability to diverse populations. Practical barriers include the need for specialized infusion facilities, biomarker testing, and high costs without subsidy, raising equity concerns, especially in rural areas. The article emphasizes that donanemab is not curative and highlights the importance of preventive care, symptomatic management, and culturally sensitive, coordinated strategies to ensure equitable access and effective dementia care. [Extracted from the article]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Australasian Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=192851254
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/10398562251393775
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: 199
    Subjects:
      – SubjectFull: Alzheimer's disease
        Type: general
      – SubjectFull: Therapeutic use of monoclonal antibodies
        Type: general
      – SubjectFull: Infusion therapy
        Type: general
      – SubjectFull: Clinical trials
        Type: general
      – SubjectFull: Biomarkers
        Type: general
      – SubjectFull: Magnetic resonance imaging
        Type: general
      – SubjectFull: Health equity
        Type: general
      – SubjectFull: Amyloid plaque
        Type: general
      – SubjectFull: Australia
        Type: general
    Titles:
      – TitleFull: Donanemab in Alzheimer's disease: Promise, limitations, and implementation challenges in Australia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dawood, Muhammad
      – PersonEntity:
          Name:
            NameFull: Saqib, Hasnain Wajeeh
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 10398562
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Australasian Psychiatry
              Type: main
ResultId 1